LDV20 Policosanol: An Explainer for Readers Researching the Ingredient in an Australian Listed Medicine
LDV20 Policosanol Explainer
- Product context: Explainer about Policosanol as it appears in LDV20, an Australian Listed Medicine (AUST L 502251) sponsored by Pure Australia Pty Ltd under the OZNEX brand.
- Dose context: LDV20 is formulated with 20 mg of Policosanol per recommended daily dose.
- Educational scope: This article explains what Policosanol is, what the published scientific literature reports on it as an individual ingredient, and how Australian Listed Medicine regulations frame consumer-facing claims. Scientific references discussed relate to the individual ingredient Policosanol and do not constitute clinical studies conducted on LDV20 itself.
- Regulator: Therapeutic Goods Administration (TGA); product listed on the Australian Register of Therapeutic Goods (ARTG).
LDV20 Policosanol: An Explainer for Readers Researching the Ingredient in an Australian Listed Medicine
Editorial Notice
This article has been prepared by the editorial team at Pure Australia for educational purposes.
It combines publicly available regulatory information, published scientific literature and ingredient-level context. It does not include a customer-experience narrative; readers seeking that format should consult the prior editorial in this series.
Scientific references discussed relate to Policosanol as an individual ingredient under various research conditions, and do not represent clinical studies conducted on LDV20 itself.
LDV20 is an Australian Listed Medicine. Always read the label and follow the directions for use.
Policosanol is the headline ingredient on the LDV20 product page. Readers arriving at this article typically fall into one of two camps: a consumer who saw "Policosanol 20 mg" on the label and wants a plain-language walk-through, or a researcher who searched for a primary-source citation map and wants every study anchored to its publisher. This article is structured for both.
1 · What Policosanol is, and where it comes from
Policosanol is a mixture of long-chain aliphatic alcohols. The most-cited clinical material is the sugarcane-wax form, but Policosanol can also be produced from rice bran or beeswax. It has been studied in cardiovascular and metabolic research for more than two decades.
Within LDV20, Policosanol is one of four active ingredients, alongside Berberine, Milk Thistle (standardised to silymarin) and Chromium. The rationale for combining four ingredients, drawn from Pure Australia's product description, is that each ingredient targets a separate physiological pathway — cardiovascular, metabolic, hepatic, and endocrine / macronutrient — so the formulation is described as offering complementary support.
2 · LDV20's Policosanol context — the 20 mg figure on the label
The LDV20 label indicates it is formulated with 20 mg of Policosanol per recommended daily dose. This is the same dosage level referenced in dose-finding clinical work on the ingredient — for example, Castaño et al. (2001) directly compared 20 mg/day with 40 mg/day.
Readers will reasonably ask: why 20 mg, and not 10 mg or 40 mg? Three relevant background facts:
- The TGA's Listed medicines overview sets the basic framework that AUST L products operate within.
- The Gouni-Berthold review (2002) in the American Heart Journal discussed 10 mg/day as approximately as effective as the same dose of simvastatin or pravastatin in early comparative work.
- The 2017 sugarcane-policosanol meta-analysis pooled RCTs with doses that bracket the 20 mg level used in LDV20.
None of the above three sources is a clinical study of LDV20. They are sources that describe how the ingredient Policosanol has been studied on its own.
3 · How Policosanol is framed under Australian Listed Medicine rules
Australian Listed Medicines operate under a tightly delimited claims framework. Three references cover the practical implications for a consumer reading the LDV20 label:
- TGA: AUST numbers on medicine labels — the labelling rules that govern how an AUST L number appears on the pack.
- TGA: Good Manufacturing Practice — the manufacturing framework applicable to LDV20.
- TGA ARTG: LDV20 (502251) — the official listing entry.
The practical effect of this framework is that LDV20 may only describe Policosanol's role using language that supports or maintains normal physiological function. It may not represent that LDV20 diagnoses, treats, cures or prevents any disease. The wording of the LDV20 product page — "supports cardiovascular health and helps maintain healthy blood lipid levels" — reflects this permitted scope.
4 · What the published research on Policosanol actually shows (as an individual ingredient)
Published studies have investigated Policosanol as an individual ingredient under various research conditions. These studies evaluated the ingredient itself rather than LDV20 specifically. The body of evidence is large enough to organise chronologically, and is geographically uneven:
| Year | Study | Population / design | Reported finding (ingredient-level) |
|---|---|---|---|
| 2002 | Gouni-Berthold et al. | Comparative pharmacology review | Reviewed Policosanol as an individual compound and discussed early comparative data. |
| 2001 | Castaño et al. | Type II hypercholesterolaemia, RCT | Compared 20 mg vs 40 mg daily dose in Policosanol-only conditions. |
| 2006 | Berthold et al. (Mayo Clinic Proc.) | US cohort, RCT | Reported no significant lipid effect in their Policosanol-only study. |
| 2006 | Dulin et al. | Healthy US adults, RCT | Reported no significant lipid effect in their Policosanol-only study. |
| 2017 | Sugarcane-policosanol meta-analysis | Pooled RCTs, dyslipidaemia | Reported reductions in total cholesterol vs placebo in Policosanol-only RCTs. |
| 2019 | Askarpour meta-analysis | Pooled RCTs, blood pressure | Reported blood-pressure-related findings in Policosanol-only cohorts. |
This evidence base, taken as a whole, supports two conclusions that an evidence-balanced consumer can hold simultaneously:
- Policosanol has been studied as an individual ingredient, has a published research base, and shows mixed but real signal in some cardiovascular endpoints when used in the 5–40 mg/day range.
- The strength of that signal is geographically uneven, with stronger and earlier positive findings concentrated in populations where the original research was conducted, and weaker or null findings in independent US-based trials.
Neither conclusion is, in itself, a statement about LDV20. The published studies did not evaluate LDV20.
5 · Where Policosanol sits inside the four-ingredient LDV20 formulation
LDV20 pairs Policosanol with three other ingredients so that the formulation addresses four distinct physiological pathways:
| Ingredient | Pathway focus | Anchor ingredient-level research |
|---|---|---|
| Policosanol (formulated with 20 mg per recommended daily dose) | Cardiovascular / lipid balance | Sugarcane meta-analysis, 2017 |
| Berberine | Metabolic / glucose | PMC review, 2021 |
| Milk Thistle (silymarin) | Hepatic / antioxidant | StatPearls, 2024 |
| Chromium | Macronutrient metabolism | NIH ODS Fact Sheet |
Across these four studies cited in this table, none evaluates LDV20 itself. The LDV20 product description, including the four-ingredient rationale, is documented on the LDV20 product page and the LDV20 Official Information Center.
6 · FAQ — Policosanol and LDV20
What is Policosanol?
Policosanol is a mixture of long-chain aliphatic alcohols. It is most commonly associated with the sugarcane-wax form but can also be produced from rice bran or beeswax. It has been studied as an individual ingredient in cardiovascular and metabolic research.
How much Policosanol does LDV20 contain?
LDV20 is formulated with 20 mg of Policosanol per recommended daily dose. See the LDV20 product page for current label information.
Is the 20 mg in LDV20 the same as the dose used in published research?
The 20 mg level intersects directly with dose-finding work on Policosanol as an individual ingredient, including Castaño et al., 2001. None of these dose-finding studies was conducted on LDV20.
Is Policosanol the same as Policosanol + Berberine combo research?
The published combination research on Policosanol combined with Berberine is discussed in Berthold et al. (2006) and the broader Policosanol review by Gouni-Berthold (2002). These studies evaluated ingredient combinations — not LDV20.
Is LDV20 an Australian Listed Medicine?
Yes. The product is listed as AUST L 502251 on the ARTG, sponsored by Pure Australia Pty Ltd, and manufactured in a TGA-GMP facility.
Where do I read the manufacturer's own information?
7 · References
Australian regulators
Policosanol — published research on the individual ingredient
Other LDV20 ingredients (ingredient-level research only)
Pure Australia internal pages referenced in this article
Editorial Disclaimer
This article is published by Pure Australia for educational and informational purposes.
It combines publicly available regulatory information with scientific literature on the individual ingredient Policosanol.
Scientific references discussed relate to Policosanol as an individual ingredient unless otherwise stated and do not represent clinical studies conducted on LDV20 itself.
LDV20 is an Australian Listed Medicine entered on the Australian Register of Therapeutic Goods (ARTG).
Always read the label and follow the directions for use.
If symptoms persist, worsen, or if you have concerns regarding your health, consult a qualified healthcare professional.